Why This Matters
GLP-1 drugs are already known to do far more than regulate blood glucose and reduce body weight. Patients taking semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have consistently reported reductions in cravings for alcohol, tobacco, and food. Clinical trials have shown reductions in alcohol use disorder symptoms. A growing body of evidence points to GLP-1 receptors distributed throughout the brain in regions governing reward processing, craving, and impulse control.